Wells Fargo & Company Celyad Oncology Sa Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.49 - $1.08 $6,027 - $13,284	-12,300 Reduced 95.57%	570 $0
Q3 2022 Nov 14, 2022	SELL	$1.57 - $2.45 $1,570 - $2,450	-1,000 Reduced 7.21%	12,870 $18,000
Q2 2022 Aug 12, 2022	SELL	$1.55 - $2.32 $5,812 - $8,700	-3,750 Reduced 21.28%	13,870 $24,000
Q1 2022 May 16, 2022	SELL	$1.72 - $4.08 $1,745 - $4,141	-1,015 Reduced 5.45%	17,620 $42,000
Q4 2021 Feb 14, 2022	BUY	$3.56 - $5.0 $38,626 - $54,250	10,850 Added 139.37%	18,635 $69,000
Q3 2021 Nov 15, 2021	BUY	$3.88 - $5.25 $5,606 - $7,586	1,445 Added 22.79%	7,785 $32,000
Q1 2021 May 13, 2021	SELL	$7.0 - $8.75 $13,601 - $17,001	-1,943 Reduced 23.46%	6,340 $45,000
Q4 2020 Feb 09, 2021	SELL	$7.13 - $9.95 $12,149 - $16,954	-1,704 Reduced 17.06%	8,283 $65,000
Q3 2020 Nov 05, 2020	BUY	$9.17 - $11.03 $37,110 - $44,638	4,047 Added 68.13%	9,987 $99,000
Q2 2020 Aug 13, 2020	SELL	$7.07 - $12.46 $7,070 - $12,460	-1,000 Reduced 14.41%	5,940 $63,000
Q1 2020 May 14, 2020	BUY	$4.18 - $12.42 $29,009 - $86,194	6,940 New	6,940 $52,000

Ticker CYAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,594,000
Market Cap $11.7M
Description
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.